Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in coronavirus disease-2019 patientsReview Published on 2021-03-242022-10-28 Journal: Pharmacogenomics [Category] COVID-19, MERS, SARS, [키워드] ABCB1 genetic polymorphism ABCB1 affected America Asia association coronavirus COVID-19 COVID-19 patient drug Efficacy Europe Genetic polymorphism genetic variability glycoprotein Lopinavir Lopinavir/ritonavir P-glycoprotein Patient phenotype Phenotypes predicted prevalent proportion risk Ritonavir safety and efficacy substrate therapeutic Toxicity treated [DOI] 10.2217/pgs-2020-0096 PMC 바로가기 [Article Type] Review
Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial확인된 COVID-19 사례(CORIPREV)의 긴밀한 접촉에서 SARS-CoV-2에 대한 노출 후 예방: 클러스터 무작위 시험을 위한 연구 프로토콜Study Protocol Published on 2021-03-222022-09-10 Journal: Trials [Category] SARS, 임상, 치료기술, 치료제, [키워드] 1:1 adaptive Analysis approach attack rate baseline Chain Reaction Chemoprophylaxis close contact Cluster Cluster randomization Clusters Combination confirmed COVID-19 case Confirmed COVID-19 infection Contact control arm correlation coefficient Course COVID-19 COVID-19 infection COVID-19 pandemic defined detect Diseases drug early treatment Efficacy epidemiological estimate evaluate excluded exposure to generalized linear mixed model Hospitalization ICC include incorporation individual Infection Infectious diseases Interim analyses interim analysis Intervention intervention arm life linear mixed model logit Lopinavir Lopinavir/ritonavir medication microbiologically modify Mortality multicenter novel Open-label oral lopinavir/ritonavir outcome participant polymerase chain polymerase chain reaction positive Post-exposure prophylaxis Prevent prevention prevention approach primary analysis Primary outcome Probability Prophylaxis protocol psychological Impact Quality of life Randomized controlled trial Registered Relative risk respiratory Respiratory failure respiratory tract risk reduction Ritonavir Safe Sample size sample size calculation SARS-CoV-2 secondary secondary attack rate Secondary outcomes Seropositivity specimen Study protocol study visit subset supplementary material Support switching symptomatic symptomatic COVID-19 Trial Trial registration ventilator [DOI] 10.1186/s13063-021-05134-7 PMC 바로가기 [Article Type] Study Protocol
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum인간 혈청에서 2차원 동위원소 희석 LC-MS/MS 방법을 통한 7가지 용도 변경 COVID-19 약물 렘데시비르(대사산물 GS-441524 포함), 클로로퀸, 히드록시클로로퀸, 로피나비르, 리토나비르, 파비피라비르 및 아지트로마이신의 동시 정량화Article Published on 2021-03-202022-09-11 Journal: Journal of pharmaceutical and biomedical analysis [Category] SARS, 신약개발, 치료제, [키워드] analogue analytical column antiviral therapy Azithromycin Bioanalytical Method Validation Chloroquine Concentration controls COVID-19 COVID-19 pandemic COVID-19 patient develop Dilution drug drug candidate drugs Efficacy and safety European Medicines Agency Favipiravir GS-441524 human serum Hydroxychloroquine inaccuracy injection Isotope Isotope dilution liquid chromatography tandem mass spectrometry (ID-LC–MS/MS) Liquid chromatography Lopinavir LOPINAVIR AND RITONAVIR mass spectrometry metabolite protein precipitation protocol provided quantification quantitative assay Remdesivir Ritonavir robust sensitivity separated serum Seven Simultaneous solid phase Tandem mass spectrometry therapeutic drug Therapeutic Drug Monitoring Treatment two-dimensional Volume were used [DOI] 10.1016/j.jpba.2021.113935 PMC 바로가기 [Article Type] Article
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19플리티뎁신: COVID-19 치료를 위한 용도 변경 약물Article Published on 2021-03-182022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] SARS, 비임상, 임상, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered animal model animal models Antiviral antiviral activity aplidin breath characterized cofactor coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 therapeutics COVID-19 vaccine demonstrated drug effective Efficacy experimental therapeutics finding Host Hydroxychloroquine interferon beta intravenously lack Large randomized clinical trials Lopinavir Lopinavir-ritonavir morbidity morbidity and mortality Multiple myeloma Plitidepsin randomized clinical trial reduce Remdesivir Repurposed drugs Ritonavir SARS-CoV-2 Science severe acute respiratory syndrome Coronavirus shown target therapeutic these compound these compounds Toxicity translation Treatment Trial trials white [DOI] 10.1128/AAC.00200-21 PMC 바로가기 [Article Type] Article
Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping reviewCOVID-19 치료를 위한 현재 연구 약물의 효능: 범위 검토Review Article Published on 2021-03-122022-08-31 Journal: Annals of Medicine [Category] 치료제, [키워드] anticoagulant therapies anticoagulant therapy Arbidol available data clinical recovery ClinicalTrials Cochrane Library conducted coronavirus Corticosteroids COVID-19 COVID-19 patients COVID-19 virus database databases drug drugs effective Efficacy eligibility criteria eligible Evidence Favipiravir Final ICTRP Immunoglobulin individuals initial interferon interferons Lopinavir Lopinavir-ritonavir mesenchymal stem cell no significant difference Plasma transfusion Pneumonia Prognosis promote Recovery time Ritonavir Sample size SARS-CoV-2 standard care stem cell Stem cell transplantation systematic literature search Tocilizumab Treatment treatment for COVID-19 treatment results treatments for COVID-19 treatments of COVID-19 Viral viral clearance virus [DOI] 10.1080/07853890.2021.1875500 PMC 바로가기 [Article Type] Review Article
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석이 포함된 살아있는 체계적인 검토의 두 번째 판(The LIVING 프로젝트)Meta-Analysis Published on 2021-03-112022-08-13 Journal: PLoS ONE [Category] Biochemistry, SARS, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval adjusted Admission aggregate data meta-analyses all age group all age groups all-cause mortality Analysis boundary bromhexine caused certainty certainty of evidence Clinical research Clinical significance Cochrane guidelines comparison Comparisons Corticosteroid Corticosteroids COVID-19 database Effect Effects eight events Evidence evidence of Families FIVE Fixed-effect meta-analysis futility GRADE high risk Hydroxychloroquine Immunoglobulin indicate indication indications individual patient data meta-analyses individuals information intensive care Intervention effects intravenous Intravenous immunoglobulin lack life Lopinavir Lopinavir-ritonavir mechanical ventilation meta-analyses Meta-analysis moderate Network meta-analysis no evidence of non-serious adverse non-serious adverse events on mechanical ventilation outcome outcomes participant Participants patient data performed Primary outcomes PRISMA Quality of life random error random errors random-effects meta-analyses randomized clinical trial randomized clinical trials rapidly spreading disease reached reduce reduced Remdesivir renal replacement therapy replacement therapy required Research risk risk of death risk ratio risks of bia Ritonavir searched second secondary Secondary outcomes sequential analysis Serious Adverse Event Serious Adverse Events single trial standard care statistically significant systematic review threshold Tocilizumab Treatment treatment for COVID-19 treatment intervention treatments of COVID-19 Trial Trial methodology trial sequential analyses trial sequential analysis website with COVID-19 [DOI] 10.1371/journal.pone.0248132 PMC 바로가기 [Article Type] Meta-Analysis
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trialCOVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-082022-09-01 Journal: Trials [Category] SARS, 임상, 진단, 치료기술, 치료제, [키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19 [DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment코로나19 치료 개선을 위한 약물유전학 접근법Review Published on 2021-03-052022-09-10 Journal: Viruses [Category] SARS, 변종, 유전자 메커니즘, 치료제, [키워드] (remdesivir ABCB1 ABCC2 addition Azithromycin Chloroquine complex coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment CYP2C8 CYP2D6 CYP3A4 CYP3A5 Dexamethasone drug drug response drug–drug interaction Drug–drug interactions Efficacy evaluated explain Factor Hydroxychloroquine IMPROVE improvement Inflammation Ivermectin Lopinavir NR1I2 oseltamivir other variants outcome pharmacogenetic pharmacogenetics Remdesivir reported Ritonavir SLCO1B1 therapy Treatment Variability variant variants Variation [DOI] 10.3390/v13030413 PMC 바로가기 [Article Type] Review
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19SARS-CoV-2 감염 및 COVID-19 치료를 위한 HIV 프로테아제 억제제 및 뉴클레오타이드 RNA 폴리머라제 억제제 재배치Review Published on 2021-03-042022-08-31 Journal: European Journal of Clinical Pharmacology [Category] SARS, 신약개발, 임상, 치료제, [키워드] addition antiretroviral Antiviral treatment approved approved drug candidate Candidates Clinical studies clinical study clinical trial clinical trials clinician Cobicistat compounds COVID-19 darunavir darunavir/cobicistat drug drugs evaluate evaluated Favipiravir followed by high variability HIV protease inhibitor HIV protease inhibitors Hospitalization indications inhibitors lack Lopinavir Lopinavir/ritonavir MERS Mortality pandemic Prevalence Protease inhibitor protease inhibitors question Remdesivir repositioning Repositioning drugs Research Result Ritonavir RNA polymerase RNA polymerase inhibitor RNA polymerase inhibitors RNA virus SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 pandemic single-stranded RNA virus sofosbuvir Study design Taking target tenofovir the SARS-CoV-2 therapeutic options Therapeutics Treatment treatment of COVID-19 Vaccine [DOI] 10.1007/s00228-021-03108-x PMC 바로가기 [Article Type] Review
Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapyQingfei Paidu 달인에 의한 약물 대사 효소 억제: COVID-19 약물 요법에서 허브-약물 상호 작용의 의미Article Published on 2021-03-012022-08-31 Journal: Food and chemical toxicology : an international jo [Category] SARS, 치료제, [키워드] AUC caused China Chinese clinical settings clinically clinician combating Combination concomitant use Corona COVID-19 COVID-19 treatment CYP3A substrate-drugs cytochrome P450 Cytochrome P450 enzymes Cytochrome P450 enzymes (CYPs/P450s) demonstrated Effect enzyme half-life Health Herb Herb-drug interactions (HDIs) in vivo inactivated inhibited inhibition inhibitory Interaction interactions Lopinavir medication modulated NADPH P450s pharmacokinetic pharmacokinetics Qingfei Paidu decoction (QPD). RATs risk significantly Spread the patient Treatment Trigger Virus Disease [DOI] 10.1016/j.fct.2021.111998 PMC 바로가기 [Article Type] Article